

CITATION REPORT

List of articles citing

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

DOI: 10.1056/nejmoa1604700

New England Journal of Medicine, 2016, 375, 209-19.

Source: <https://exaly.com/paper-pdf/65072032/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
438	Oncology providers' Perspectives on endocrine therapy prescribing and management. 2016 , 10, 2007-2019		14
437	Estrogens - the Saviors of Cognitive Function?. 2016 , 11, 238-239		0
436	Recent advances in the medical treatment of breast cancer. 2016 , 5, 2786		8
435	How Do We Best Ensure That Rosebuds Are Gathered?. 2016 , 12, 1157-1159		
434	Are another 5 years of adjuvant aromatase inhibitor therapy needed?. 2016 , 8, 207-209		
433	Supportive care of women with breast cancer: key concerns and practical solutions. 2016 , 205, 471-475		24
432	Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer. 2016 , 28, 455-460		7
431	ASCO 2016: highlights in breast cancer. 2016 , 9, 211-214		4
430	Scientific surgery. 2016 , 103, 1566-1566		
429	Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. 2016 , 12, 1148-1156		5
428	Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review. 2016 , 35, 427-37		53
427	Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence. 2016 , 68, 176-178		2
426	Acute acalculous cholecystitis due to breast cancer metastasis to the cystic duct. 2016 , 2, 111		6
425	Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016 , 375, 1591	59.2	4
424	Aromatasehemmer bei Brustkrebs: Therapie auf 10 Jahre verläßern?. 2016 , 19, 39-39		
423	Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. 2016 , 28, 461-468		4
422	Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy. 2016 , 59, 756-771		2

421	Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention. <i>New England Journal of Medicine</i> , 2016 , 375, 274-5	59.2	1
420	Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?. 2017 , 24, 614-617		31
419	Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis. 2017 , 111, 66-80		35
418	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2017 , 35, 1341-1367		75
417	Extended adjuvant endocrine therapy - A standard to all or some?. 2017 , 32, 112-118		7
416	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. 2017 , 97, 147-152		21
415	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. 2017 , 35, 1041-1048		63
414	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. 2017 , 18, 4		13
413	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. 2017 , 17, 297-310		3
412	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). 2017 , 75, 284-298		265
411	Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review. 2017 , 162, 375-388		12
410	Extended Endocrine Therapy: Is 5 Years Enough?. 2017 , 19, 16		3
409	Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. 2017 , 163, 311-319		14
408	MR imaging features associated with distant metastasis-free survival of patients with invasive breast cancer: a case-control study. 2017 , 162, 559-569		20
407	A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy. 2017 , 11, 477-485		14
406	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. 2017 , 7, 1-12		127
405	Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review. 2017 , 3, 402-409		14
404	Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials. 2017 , 34, 131		9

403	How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?. 2017 , 3, 20	27
402	Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. 2017 , 18, 821-830	9
401	Breast Cancer Detected at Screening US: Survival Rates and Clinical-Pathologic and Imaging Factors Associated with Recurrence. 2017 , 284, 354-364	20
400	Family-building After Breast Cancer: Considering the Effect on Adherence to Adjuvant Endocrine Therapy. 2017 , 17, 165-170	7
399	Second Opinions From Medical Oncologists for Early-Stage Breast Cancer: Prevalence, Correlates, and Consequences. 2017 , 3, 391-397	17
398	Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. 2017 , 28, 487-496	95
397	Management of hot flashes in women with breast cancer receiving ovarian function suppression. 2017 , 52, 82-90	23
396	Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women. 2017 , 9, 236-241	3
395	Recurrence dynamics of breast cancer according to baseline body mass index. 2017 , 87, 10-20	27
394	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. 2017 , 18, 1502-1511	70
393	Extended adjuvant therapy: the role of subset analyses. 2017 , 18, 1431-1433	
392	Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy. 2017 , 24, C21-C29	3
391	A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR Early-Stage Breast Cancer with One to Three Positive Nodes. 2017 , 23, 7217-7224	18
390	Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. 2017 , 60, 53-59	17
389	Long-term efficacy and safety of aromatase inhibitor use for leiomyomatosis peritonealis disseminata. 2017 , 43, 1489-1492	4
388	De-escalating and escalating systemic therapy of early breast cancer. 2017 , 34 Suppl 1, S5-S9	1
387	Prognostic assessment and systemic treatments of invasive local relapses of hormone receptor-positive breast cancer. 2017 , 35, 162-168	0
386	Luteinizing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. 2017 , 18, 1357-1362	4

385	Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer. 2017 , 9, 183-187	0
384	Costs and Benefits of Extended Endocrine Strategies for Premenopausal Breast Cancer. 2017 , 15, 1015-1021	7
383	Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. 2017 , 166, 657-668	37
382	Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy. 2017 , 12, 146-151	7
381	Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer. 2017 , 12, 138-144	2
380	Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study. 2017 , 166, 541-547	18
379	Hormonal Changes and Sexual Dysfunction. 2017 , 101, 1135-1150	4
378	Comparison of distress in breast cancer survivors treated with different adjuvant endocrine therapies: a single-centre cross-sectional study. 2017 , 27, 271-277	3
377	Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice. 2017 , 24, 2881-2888	35
376	Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. 2017 , 13, 2733-2736	1
375	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017 , 377, 1836-1846	59.2 610
374	Endocrine Therapies in the Adjuvant and Advanced Disease Settings. 2017 , 557-568	
373	Breast cancer treatment-induced cardiotoxicity. 2017 , 16, 1021-1038	28
372	Adjuvant ovarian suppression for resected breast cancer: 2017 critical assessment. 2017 , 166, 1-13	5
371	Preventing invasive breast cancer using endocrine therapy. 2017 , 34 Suppl 1, S47-S54	13
370	Breast cancer milestones 2007-2016. 2017 , 10, 27-32	
369	Highlights of the San Antonio Breast Cancer Symposium 2016. 2017 , 13, 1291-1295	
368	Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study. 2017 , 24, 774-782	14

- 367 A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice. **2017**, 3, 735-736
- 366 Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. **2017**, 17, 11-17 43
- 365 Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. **2017**, 3, 186-193 17
- 364 Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. **2017**, 31, 173-180 3
- 363 Optimal duration of adjuvant endocrine therapy: how to apply the newest data. **2017**, 9, 679-692 10
- 362 Endokrine antihormonelle Therapie in der Prämenopause. **2017**, 27, 147-152
- 361 Standard Changing News der Senologie und Gynäkologischen Onkologie. **2017**, 46, 648-654
- 360 Letrozole-induced hepatitis with autoimmune features: a rare adverse drug reaction with review of the relevant literature. **2017**, 2017, omx074 5
- 359 Hormone Therapy in Breast Cancer: Where do We Stand?. **2017**, 06,
- 358 ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy. **2017**, 10, 4859-4867 8
- 357 Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. **2017**, 28, e45 22
- 356 Transcription Factors in Breast Cancer-Lessons From Recent Genomic Analyses and Therapeutic Implications. **2017**, 107, 223-273 10
- 355 Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. **2017**, 7, 26 49
- 354 Endokrine antihormonelle Therapie in der Prämenopause. **2017**, 20, 151-156
- 353 Endocrine Therapy in Older Women with Early-Stage Hormone Sensitive Breast Cancer. **2017**, 06,
- 352 De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. **2017**, 28, 1700-1712 586
- 351 gene polymorphism and colorectal cancer etiology in Saudi population: case-control study. **2017**, 10, 4559-4567 2
- 350 Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. **2017**, 13, e505-e515 8

349	Improving Breast Cancer Risk Assessment Versus Implementing Breast Cancer Prevention. 2017 , 35, 702-704	2
348	Long-Term Follow-Up of the Intergroup Exemestane Study. 2017 , 35, 2507-2514	13
347	Standard and Genomic Tools for Decision Support in Breast Cancer Treatment. 2017 , 37, 106-115	5
346	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. 2017 , 8, 55550-55561	10
345	The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications. 2018 , 80, S348-S351	3
344	Longitudinal Effects of Adjuvant Endocrine Therapy on the Quality of Life of Post-menopausal Women with Non-metastatic ER+ Breast Cancer: A Systematic Review. 2018 , 2, 359-369	4
343	Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register. 2018 , 57, 935-940	12
342	Representation of obese participants in obesity-related cancer randomized trials. 2018 , 29, 1582-1587	9
341	SULFATION PATHWAYS: Steroid sulphatase inhibition via aryl sulphamates: clinical progress, mechanism and future prospects. 2018 , 61, T233-T252	36
340	Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer. 2018 , 19, 24	21
339	Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). 2018 , 110,	85
338	Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. 2018 , 78, 237-245	15
337	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. 2018 , 4, 545-553	162
336	Breast Cancer, Including Brief Discussion of Male Breast Cancer. 2018 , 375-396	
335	AR Expression in Breast Cancer CTCs Associates with Bone Metastases. 2018 , 16, 720-727	37
334	Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?. 2018 , 12, 348-356	27
333	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. 2018 , 765-785	
332	The breast tumor microenvironment: role in cancer development, progression and response to therapy. 2018 , 18, 227-243	55

331	Adjuvant Endocrine Therapy. 2018 , 173, 15-29	9
330	Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence. 2018 , 169, 153-162	5
329	Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge. 2018 , 38, 161-173	26
328	Adjuvant Endocrine Therapy. 2018 , 736-751.e4	1
327	Endocrine Therapy for Breast Cancer. 2018 , 907-923.e6	2
326	Adjuvant Endocrine Therapy. 2018 , 427-438	
325	Hormone receptor positive breast cancer: state of the art. 2018 , 30, 51-54	10
324	Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. 2018 , 168, 523-530	5
323	Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer. 2018 , 30, e9-e15	12
322	Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. 2018 , 168, 169-178	1
321	Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. 2018 , 12, 268-275	6
320	Searching for the IDEAL Duration of Adjuvant Endocrine Therapy. 2018 , 110,	
319	Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. 2018 , 19, 26	32
318	Cardiovascular Risk in Breast Cancer Patients Receiving Estrogen or Progesterone Antagonists. 2018 , 20, 48	2
317	Mitochondria Remodeling in Cancer. 2018 , 153-191	
316	The challenges of modeling hormone receptor-positive breast cancer in mice. 2018 , 25, R319-R330	20
315	Current Issues in the Overdiagnosis and Overtreatment of Breast Cancer. 2018 , 210, 285-291	29
314	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. 2018 , 110,	76

313	Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?. 2018 , 167, 235-248	6
312	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. 2018 , 25, R83-R113	11
311	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. 2018 , 19, 127-138	62
310	Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. 2018 , 110,	2
309	Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. 2018 , 9, 8810-8822	11
308	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. 2018 , 36, 1941-1948	73
307	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. 2018 , 36, 1020-1044	83
306	Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. 2018 , 36, 563-571	13
305	What Is the Role of Symptom Management and Patient-Reported Outcomes in Adherence to Aromatase Inhibitors?. 2018 , 36, 308-309	4
304	Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials. 2018 , 7, 449-457	6
303	Adjuvante endokrine Therapie beim frühen Mammakarzinom. 2018 , 51, 972-979	
302	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 1946-1953	59.2 2
301	Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer. 2018 , 10, 241-250	8
300	CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. 2018 , 20, 149	7
299	Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. 2018 , 6, 141-156	17
298	Potential Mechanisms of Age Acceleration Caused by Estrogen Deprivation: Do Endocrine Therapies Carry the Same Risks?. 2018 , 2, pky035	6
297	Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer. 2018 , 9, 566-574	5
296	Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. 2018 , 29, 2334-2340	54

295	Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. 2018 , 18, 1027	3
294	Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer. 2018 , 18, 977	8
293	Skeletal Complications of Breast and Prostate Cancer Therapies. 2018 , 775-780	1
292	Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. 2018 , 27, 1332-1341	17
291	Bone health evaluation one year after aromatase inhibitors completion. 2018 , 117, 54-59	7
290	Managing side effects in adjuvant endocrine therapy for breast cancer. 2018 , 18, 1101-1112	32
289	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. 2018 , 70, 138-143	6
288	Fulvestrant in management of hormone receptor-positive metastatic breast cancer. 2018 , 14, 1789-1800	1
287	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the Women@ Health Initiative Randomized Clinical Trial. 2018 , 4, e181212	40
286	Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women@ Sexual Health. 2018 , 25, 596-608	84
285	Overview of Breast Cancer Therapy. 2018 , 13, 339-354	120
284	Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer. 2018 , 14, e238-e242	2
283	A rude awakening from tumour cells. 2018 , 554, 35-36	7
282	Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. 2018 , 172, 167-177	16
281	Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years. 2018 , 18, e1353-e1360	6
280	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. 2018 , 4, 1700-1706	101
279	Optimal management of luminal breast cancer: how much endocrine therapy is long enough?. 2018 , 10, 1758835918777437	6
278	Patterns of Occurrence and Outcomes of Contralateral Breast Cancer: Analysis of SEER Data. 2018 , 7,	12

277	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. 2018 , 320, 167-176	136
276	Successful Targeted Therapies for Breast Cancer: the Worcester Foundation and Future Opportunities in Women@ Health. 2018 , 159, 2980-2990	13
275	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. 2018 , 171, 121-129	7
274	Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. 2018 , 89, 280-296	21
273	The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. 2018 , 20, 23	18
272	Endocrine therapy for breast cancer in the primary care setting. 2018 , 25, 285-291	24
271	Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. 2018 , 70, 118-126	9
270	Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. 2018 , 2, 574-588	13
269	Update Mammakarzinom 2018 (Teil 1) Primäres Mammakarzinom und Biomarker. 2018 , 15, 86-94	
268	Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. 2019 , 24, 1432-1438	7
267	A Review of Local and Systemic Therapy in Breast Cancer. 2019 , 637-690	
266	Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype?. 2019 , 30, 1879-1886	3
265	Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary. 2019 , 211, 224-229	8
264	Adjuvante endokrine Therapie beim Mammakarzinom: Was ist der aktuelle Stand?. 2019 , 52, 354-359	
263	Adjuvant Endocrine Therapy. 2019 , 135-152	
262	Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. 2019 , 105, 296-306	26
261	A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. 2019 , 8, BMT22	4
260	Cardiometabolic Effects of Endocrine Treatment of Estrogen Receptor-Positive Early Breast Cancer. 2019 , 3, 1283-1301	9

259	Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. 2019 , 37, 3425-3435	27
258	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. 2019 , 22, 387-398	1
257	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. 2019 , 3, pkz050	6
256	Dermatologic conditions in women receiving systemic cancer therapy. 2019 , 5, 285-307	5
255	Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research. 2019 , 125, 4452-4461	7
254	Leukocytoclastic vasculitis associated with use of aromatase inhibitors. 2019 , 49, 1162-1167	3
253	Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies. 2019 , 58, 1581-1593	2
252	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. 2019 , 37, 3152-3165	63
251	The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis. 2019 , 19, e731-e740	8
250	Evaluating triptorelin as a treatment option for breast cancer. 2019 , 20, 1809-1818	1
249	Breast cancer. 2019 , 5, 66	698
248	Breast Cancer Treatment: A Review. 2019 , 321, 288-300	1202
247	Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. 2019 , 174, 785-794	22
246	Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use?. 2019 , 25, 7-8	
245	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. 2019 , 74, 29-34	11
244	Absolute Clinical Radiation Oncology Review. 2019 ,	2
243	Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. 2019 , 30, 567-574	11
242	Symptom Map of Endocrine Therapy for Breast Cancer: A Scoping Review. 2019 , 42, E19-E30	5

241	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. 2019 , 154, 29-37	18
240	Adjuvant Systemic Therapy in Breast Cancer. 2019 , 179-194	
239	The assessment of 8th edition AJCC prognostic staging system and a simplified staging system for breast cancer: The analytic results from the SEER database. 2019 , 25, 838-847	10
238	Management of Breast Cancer in Older Women. 2019 ,	
237	Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up. 2019 , 37, 1515-1516	1
236	Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. 2019 , 46, 19-24	7
235	Extended Adjuvant Therapy With Aromatase Inhibitors for Early Breast Cancer: A Meta-analysis of Randomized Controlled Trials. 2019 , 19, e578-e588	3
234	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. 2019 , 145, 2114-2121	2
233	Bone health in women with breast cancer. 2019 , 22, 589-595	7
232	Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study. 2019 , 42, 352-362	22
231	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019 , 120, 959-967	8.7 3
230	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. 2019 , 37, 423-438	218
229	Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools. 2019 , 37, 1365-1369	9
228	Locally advanced breast cancer in Brazil: current status and future perspectives. 2019 , 13, 895	4
227	Breast Cancer. 2019 , 233-264	0
226	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. 2019 , 21, 153	7
225	Understanding the unmet sexual health needs of women with breast cancer. 2019 , 26, 811-813	
224	Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. 2019 , 1-26	

223	Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. 2019 , 44, 1-14	25
222	Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. 2019 , 16, 296-311	33
221	Unemployment following breast cancer diagnosis: A population-based study. 2019 , 44, 24-28	10
220	Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). 2019 , 76, 120-131	5
219	Cancer Policy: Pharmaceutical Safety. 2019 ,	
218	Cancer Drug Toxicity: Moving from Patient to Survivor. 2019 , 171, 107-118	1
217	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. 2019 , 20, 88-99	58
216	Competing risks of extended adjuvant aromatase inhibitors. 2019 , 20, 8-9	1
215	Decision Pathways in Breast Cancer Management. 2019 , 3-97	
214	Endocrine Therapy Nonadherence and Discontinuation in Black and White Women. 2019 , 111, 498-508	29
213	Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study. 2019 , 5, 25-39	17
212	Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. 2020 , 179, 217-227	7
211	Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. 2020 , 179, 275-285	11
210	Cancer of the Breast. 2020 , 1560-1603.e12	6
209	Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormone-positive breast cancer. 2020 , 26, 133-138	12
208	CDK4/6 inhibitors in breast cancer - from models to clinical trials. 2020 , 59, 219-232	6
207	Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis. 2020 , 22, 263-276	3
206	Role of Lipoproteins in the Microenvironment of Hormone-Dependent Cancers. 2020 , 31, 256-268	8

205	Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015. 2020 , 126, 958-970	7
204	Window of opportunity treatment in breast cancer. 2020 , 90, 34-40	1
203	Landmark trials in the medical oncology management of early stage breast cancer. 2020 , 47, 278-292	0
202	Clinical utility of routine parathyroid hormone measurement in women commenced on endocrine therapy for hormone sensitive breast cancer. 2020 , 4, 14-14	
201	A Short-Term Effect of Wearable Technology-Based Lifestyle Intervention on Body Composition in Stage I-III Postoperative Breast Cancer Survivors. 2020 , 10, 563566	0
200	How to treat lobular cancer in the adjuvant setting?. 2020 , 32, 561-567	2
199	Extended Endocrine Therapy for Early-Stage Breast Cancer: How Do We Decide?. 2020 , 22, 123	1
198	Management of hormone receptor-positive, HER2-negative early breast cancer. 2020 , 47, 187-200	8
197	Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. 2020 , 31, 1359-1365	3
196	Receipt of psychological counseling and integrative medicine services among breast cancer survivors with anxiety. 2020 , 184, 301-310	0
195	New Insights into Therapy-Induced Progression of Cancer. 2020 , 21,	6
194	Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index. 2020 , 10, 16850	6
193	Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study. 2020 , 184, 783-795	1
192	Adjuvante endokrine Therapie beim primären Mammakarzinom. 2020 , 14, 27-42	
191	A review of clinical and emerging biomarkers for breast cancers: towards precision medicine for patients. 2020 , 1-14	
190	Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. 2020 , 184, 965-975	3
189	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. 2020 , 5, e000743	4
188	Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer. 2020 , 21, 84	1

187	Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2557-2570	59.2	38
186	Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report. 2020 , 34, 100634		0
185	Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. 2020 , 9, 5035-5050		3
184	Breast cancer: are long-term and intermittent endocrine therapies equally effective?. 2020 , 146, 2041-2049		3
183	Cost-effectiveness analysis of endocrine therapy alone versus partial-breast irradiation alone versus combined treatment for low-risk hormone-positive early-stage breast cancer in women aged 70 years or older. 2020 , 182, 355-365		8
182	High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer. 2020 , 183, 41-48		4
181	Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer. 2020 , 182, 259-266		
180	Osteoporosis epidemiology using international cohorts. 2020 , 32, 387-393		9
179	The maintenance effect of acupuncture on the side effects of breast cancer endocrine therapy: A protocol for systematic review and meta analysis. 2020 , 99, e20567		
178	Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer. 2020 , 9, 33		1
177	Adjuvant and neoadjuvant therapy for breast cancer. 2020 , 50, 225-229		26
176	Molecular natural history of breast cancer: Leveraging transcriptomics to predict breast cancer progression and aggressiveness. 2020 , 9, 3551-3562		3
175	Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value. 2020 , 10, 4660		9
174	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. 2020 , 26, 2556-2564		32
173	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. 2020 , 37, 331-348		3
172	Case 7-2020: A 52-Year-Old Man with a Mass in the Left Breast. <i>New England Journal of Medicine</i> , 2020 , 382, 856-864	59.2	
171	Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. 2020 , 141, 549-559		34
170	Extended endocrine therapy in early breast cancer: how long and who for?. 2020 , 16, 4327-4336		2

169	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. 2020 , 11, 369-379	12
168	Survivors of primary breast cancer 5 years after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study. 2020 , 301, 761-767	3
167	Healthcare system distrust and the breast cancer continuum of care. 2020 , 180, 33-44	10
166	The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. 2021 , 28, 67-74	2
165	Update on systemic treatment for newly diagnosed inflammatory breast cancer. 2021 , 29, 1-12	3
164	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. 2021 , 27, 504-512	3
163	Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. 2021 , 186, 115-123	6
162	Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR Early-stage Breast Cancer for 10 Years of Endocrine Therapy. 2021 , 27, 311-319	17
161	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. 2021 , 185, 205-214	8
160	Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors. 2021 , 29, 2385-2394	5
159	The role of complementary and alternative methods in the treatment of pain in patients with cancer - current evidence and clinical practice: a narrative review. 2021 , 25, 88-94	0
158	Impact of breast cancer and its treatment on bone loss and fracture risk pathophysiology and management. 2021 , 1395-1406	
157	Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis. 2021 , 28, 630-643	2
156	Association of Axillary Lymph Node Evaluation With Survival in Women Aged 70 Years or Older With Breast Cancer. 2020 , 10, 596545	2
155	A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting. 2021 , 1	0
154	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. 2021 , 12,	4
153	Quality of Life (QoL) in Postmenopausal Breast Cancer Patients Receiving Adjuvant Hormonal Therapy. 1	1
152	Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice. 2021 , 187, 455-465	0

151	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. 2021 , 7, 609-615	4
150	Perils of prolonged ovarian suppression and hypoestrogenism in the treatment of breast cancer: Is the risk of treatment worse than the risk of recurrence?. 2021 , 525, 111181	2
149	Ultrasound-Based Radiomics Analysis for Predicting Disease-Free Survival of Invasive Breast Cancer. 2021 , 11, 621993	6
148	Understanding Molecular Process and Chemotherapeutics for the Management of Breast Cancer. 2021 , 15, 69-84	1
147	Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells. 2021 , 11, 659963	7
146	Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. 2021 , 7, 66	8
145	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. 2021 , 25, 409-424	4
144	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. 2021 , 149, 117-127	4
143	Breast cancer. 2021 , 23, 5-40	3
142	Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer. 2021 , 39, 1506-1507	
141	Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. 2021 , 41, 1-15	1
140	Selection of Adjuvant Endocrine Therapy for Women With Breast Cancer in Menopausal Transition: Is It Simpler Than We Thought?. 2021 , 113, 1444-1446	1
139	Extending Adjuvant Endocrine Therapy for 10 Years: A Mixed-Methods Analysis of Women's Decision Making in an Online Breast Cancer Forum. 2021 , 9,	0
138	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. 2021 , 148, 55-61	13
137	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021 , 385, 395-405	59.2 8
136	Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. 2021 , 12, 713700	5
135	De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough?. 2021 , 274, 654-663	2
134	Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatment. 2021 , 531, 111321	3

133	Hormonoterapia adyuvante en c�ncer de mama. Revisi�n de la Evidencia y Abordaje Terap�utico en el Instituto Instituto Nacional de Cancerolog�a, Bogot�Colombia. 25, 130-141	
132	Cost-Effectiveness Analysis of No Adjuvant Therapy Versus Partial Breast Irradiation Alone Versus Combined Treatment for Treatment of Low-Risk DCIS: A Microsimulation. 2021, 17, e1055-e1074	0
131	Weight Change in Post-Menopausal Women with Breast Cancer during Chemotherapy-Perspectives on Nutrition, Activity and Bone Metabolism: An Interim Analysis of a 5-Year Prospective Cohort. 2021, 13,	1
130	A new clinically-relevant rat model of letrozole-induced chronic nociceptive disorders. 2021, 425, 115600	1
129	Competing Nomogram for Late-Period Breast Cancer-Specific Death in Patients with Early-Stage Hormone Receptor-Positive Breast Cancer. 2021,	0
128	Extended adjuvant aromatase inhibitor therapy: less is more.. 2021, 2, 996-998	
127	Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer. 2021, 15, 2051-2061	1
126	NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers. 2021, 7, eabc8145	1
125	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. 2021, 22, 1458-1467	7
124	Second invasive breast cancers in patients treated with breast-conserving therapy. 2021, 47, 2492-2498	1
123	Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. 2021, 32, 1256-1266	2
122	Systemic therapy for older patients with early breast cancer. 2021, 100, 102292	1
121	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. 2021, 23, 1	14
120	The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. 2021, 21, 78	3
119	Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. 2021, 13,	1
118	Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer. 2021, 17, 12	
117	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. 2021, 15, 1178223421995854	
116	Endocrine Therapy in Clinical Practice. 2019, 215-240	1

115	Onkologika. 2016 , 583-619	1
114	Onkologika. 2017 , 597-639	1
113	Do we still need breast cancer screening in the era of targeted therapies and precision medicine?. 2020 , 11, 105	16
112	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". 2016 , 13, e1002204	81
111	Comparative Study for Clinical Outcomes of Triple-Positive and Triple-Negative Breast Cancer: Long-term Results in 161 Patients Followed in a Single Center. 2020 , 8, 78-84	3
110	The effects of adjuvant endocrine therapy on bone health in women with breast cancer. 2019 , 241, R111-R124	18
109	Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. 2017 , 8, 8406-8419	25
108	New insights into acquired endocrine resistance of breast cancer. 2019 , 2, 198-209	19
107	Estrogen Receptor (ER) Targeting Compounds and Derivatives: Recent Advances in Structural Modification and Bioactivity. 2019 , 19, 1318-1337	3
106	Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis. 2020 , 35, e403	4
105	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. 2019 , 30, e86	10
104	Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death. 2019 , 22, 96-108	6
103	Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan. 2020 , 32, 175-180	3
102	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. 2021 , OP2100482	1
101	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. 2021 , 32, 1571-1581	36
100	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. 2021 ,	1
99	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. 2016 , 1-21	
98	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. 2017 , 1-34	

- 97 Invasive Carcinomas. **2018**, 191-232 1
- 96 News in hormonal therapy for breast cancer. **2017**, 11, 257-262
- 95 Menopause Symptoms. **2018**, 277-299 0
- 94 Onkologika. **2018**, 645-691 1
- 93 Adjuvant Endocrine Therapy for Breast Cancer. **2019**, 413-432
- 92 Onkologika. **2019**, 817-875
- 91 Adjuvant Systemic Therapy: Endocrine Therapy. **2019**, 103-127
- 90 Adjuvant Hormone Therapy for Breast Cancer. **2019**, 479-487
- 89 Bone Health in Patients with Breast Cancer. **2019**, 15, 16 1
- 88 Onkologika. **2020**, 671-732 1
- 87 Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
- 86 Is the extension of adjuvant hormone therapy for breast cancer justified?. **2020**, 74-79
- 85 Surgical Cases of Pulmonary Nodules in Patients with Breast Cancer. **2021**, 61, 389-395
- 84 Early Recurrence of Breast Cancer after the Primary Treatment: Analysis of Clinicopathological and Radiological Predictive Factors. **2020**, 81, 395
- 83 Adjuvante Therapie des Mammakarzinoms. **2020**, 403-419
- 82 Cardio-Oncology: Preventing Broken Hearts in Women with Breast Cancer. **2020**, 217-236
- 81 Precautions for Patients Taking Aromatase Inhibitors. **2020**, 11, 184-189
- 80 Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers. **2021**, 11, 660318 0

79	The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience. 2021 , 13,	1
78	Adjuvant Endocrine Therapy in Early Breast Cancer. 2021 , 165-177	
77	Digestive Disease Week And American Society of Clinical Oncology. 2016 , 41, 446-51	
76	Endocrine Therapy for Early Breast Cancer: Updated Review. 2017 , 17, 405-411	33
75	Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline. 2016 , 7, 666-671	
74	Genomic Testing in the Management of Early-Stage Breast Cancer. 2017 , 24, 229-238	1
73	Mammakarzinom. 2022 , 340-351	
72	Endocrine Treatment for Breast Cancer Patients Revisited-History, Standard of Care, and Possibilities of Improvement. 2021 , 13,	3
71	Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. 2021 , 1	
70	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.. 2021 , 2, 514-530	3
69	Copy number heterogeneity identifies ER+ breast cancer patients with adverse outcome after adjuvant endocrine therapy.	
68	Is it time to consider the Androgen receptor as a therapeutic target in breast cancer?. 2021 ,	3
67	Onkologika. 2021 , 579-638	
66	Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA trial.. 2022 ,	0
65	Long-term control of recurrent disease in a patient with hormones receptor-positive breast cancer. 2021 , 1, 56	
64	Blocking the Increase of Intracellular Deuterium Concentration Prevents the Expression of Cancer-Related Genes, Tumor Development, and Tumor Recurrence in Cancer Patients.. 2022 , 29, 10732748211068963	
63	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials.. 2021 , 11, 829875	0
62	How we treat HR-positive, HER2-negative early breast cancer.. 2022 ,	0

61	Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study.. 2022,	0
60	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation: A Post Hoc Analysis of a Randomized Clinical Trial.. 2022,	2
59	Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy.. 2022,	0
58	Feasibility Trial to Evaluate Tendon Stiffness Obtained from Shear Wave Elastography Imaging as a Biomarker of Aromatase Inhibitor-Induced Arthralgias.. 2022, 11,	1
57	Management of genitourinary syndrome of menopause in breast cancer survivors: An update.. 2022 , 13, 71-100	2
56	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.. 2022, 164, 52-61	
55	Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.. 2022, 193, 203	3
54	Feasibility of a pharmacist-led symptom monitoring and management intervention to improve breast cancer endocrine therapy adherence.. 2022,	1
53	Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.. 2022, 105, 102375	4
52	Treatment and Survivorship Interventions to Prevent Poor Body Image Outcomes in Breast Cancer Survivors.. 2021, 13, 701-709	2
51	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics.. 2021,	1
50	Systemtherapie beim Mammakarzinom. 2022, 28, 77-90	
49	Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database.. 2021, 14,	0
48	Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation.. 2022, 8, 53	0
47	Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study. 2022,	
46	Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer.. 2022,	
45	The Applications of Plasma Cell-free DNA in Cancer Detection: Implications in the Management of Breast Cancer Patients. 2022, 103725	
44	Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone ReceptorPositive Breast Cancer. 2022, 1-13	0

- 43 The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors.
- 42 Preventing late recurrence in hormone receptor-positive early breast cancer: a review. **2022**, 172, 53-64
- 41 Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer. *Literature Review*. **2022**, 29, 4956-4969 ○
- 40 Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer. 13,
- 39 Taxane chemotherapy leads to breast cancer dormancy escape by stromal injury mediated IL-6/MAP2K signaling.
- 38 Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy. *British Journal of Cancer*, 8.7
- 37 Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.
- 36 Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor Positive Breast Cancer. **2022**, 5, e2225485 ○
- 35 Determinants and effectiveness of extending the duration of adjuvant hormone therapy beyond 5 years in breast cancer patients. ○
- 34 Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?. **2022**, 110, 102445 1
- 33 Comparison of Time-Varying Pattern of Recurrence in Chinese Breast Cancer Patients with Different Molecular Subtypes: A Single-Center Retrospective Study. **2022**, 24, 451-469 ○
- 32 Increased Clinical Pain Locations and Pain Sensitivity in Women after Breast Cancer Surgery. Publish Ahead of Print, ○
- 31 Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients. 1
- 30 TGF- β at the crossroads of multiple prognosis in breast cancer, and beyond. **2022**, 121011 ○
- 29 Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy. *IA Review Study*. **2022**, 18, 292-298 ○
- 28 Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study. **2022**, 66, 89-96 ○
- 27 Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. 12, ○
- 26 Adherence to adjuvant hormonal therapy in localised breast cancer. 1

25	Extended adjuvant endocrine therapy for women with hormone receptor-positive early breast cancer: A meta-analysis with trial sequential analysis of randomized controlled trials. 12,	0
24	Neoplasms of the Breast. 1-62	0
23	Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests. 2022 , 23, 13604	0
22	Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: A systematic review with network meta-analysis. 2023 , 181, 103898	0
21	The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health. 2022 , 24,	0
20	Identifying the predictors of adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status.	0
19	Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis.	0
18	Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors.	1
17	Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor-positive breast cancer. 12,	0
16	Cost-Effectiveness Analysis of Ultra-Hypofractionated Whole Breast Radiation Therapy Alone vs. Endocrine Therapy Alone or Combined Treatment for Low-Risk ER-positive Early-Stage Breast Cancer in Women Age 65 and Older. 2022 ,	0
15	Diagnostics and management of vulvovaginal atrophy according to the international guidelines. 2022 , 7, 110-121	0
14	Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients. 2023 , 30, 1461-1472	1
13	Management of bone loss due to endocrine therapy during cancer treatment.	0
12	Tailoring Treatment for Patients with Inflammatory Breast Cancer.	0
11	Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study. Volume 15, 251-261	0
10	Cognitive function among women with breast cancer receiving endocrine therapy: what are the impacts?.	0
9	Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer. Publish Ahead of Print,	0
8	Prolonged endocrine therapy in the management of hormone receptor-positive early-stage breast cancer: What is the appropriate duration?. 2023 , 49, 1079-1082	0

- 7 Hämatologische Neoplasien und solide Tumore. **2022**, 85-151 ○
- 6 Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia (AIA) in Breast Cancer Patients. **2023**, 13, 452 ○
- 5 Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. ○
- 4 Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurement. ○
- 3 Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials. **2023**, 13, e070972 ○
- 2 Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. ○
- 1 Encapsulation for breast cancer treatment. **2023**, 661-720 ○